- Conditions
- Episodic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
- Conditions
- Episodic Cluster Headache
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • Santa Monica, California + 14 more
- Conditions
- Migraine Headache
- Interventions
- LY2951742, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 37
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 80
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Erenumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
- Conditions
- Chronic Cluster Headache
- Interventions
- Galcanezumab 300 mg, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Monica, California • Stanford, California + 10 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Apple Valley, California • Los Angeles, California + 44 more
- Conditions
- Migraine Disorders
- Interventions
- Capsaicin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Encino, California • Glendale, California + 9 more
- Conditions
- Migraine Disorders
- Interventions
- LY2951742, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Migraine, Episodic Migraine
- Interventions
- Galcanezumab, Rimegepant, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 77
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
- Conditions
- Episodic Cluster Headache, Chronic Cluster Headache
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 8 more
- Conditions
- Migraine Headache
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more
- Conditions
- Chronic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Healthy
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Encino, California • Fullerton, California + 47 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- LY2951742, Placebo- oral, Placebo - SC, Celecoxib
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Anaheim, California • San Diego, California + 31 more
- Conditions
- Healthy
- Interventions
- Galcanezumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • Ocoee, Florida + 15 more